Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | CASP6 | P55212 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | TPMT | P51580 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL865237 | 0.87 | LMNA (0.65) | LMNACASP6ALDH1A1TSHRTPMT | |
| SCHEMBL29111608 | 0.82 | CASP6 (0.55) | LMNACASP6ALDH1A1MEN1KMT2A | |
| SCHEMBL30629252 | 0.82 | CASP6 (0.55) | LMNACASP6ALDH1A1MEN1KMT2A | |
| SCHEMBL4632273 | 0.82 | LMNA (0.64) | LMNACASP6ALDH1A1TSHRTPMT | |
| SCHEMBL1759189 | 0.81 | MAPT (0.50) | LMNAALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL452336 | 0.81 | ALDH1A1 (0.58) | LMNACASP6ALDH1A1TSHRTPMT | |
| SCHEMBL2894909 | 0.81 | CASP6 (0.53) | LMNACASP6ALDH1A1MEN1KMT2A | |
| SCHEMBL3770749 | 0.81 | TTR (0.62) | LMNACASP6ALDH1A1MEN1KMT2A | |
| SCHEMBL3146159 | 0.80 | CASP6 (0.60) | LMNACASP6ALDH1A1MEN1KMT2A | |
| SCHEMBL1509549 | 0.79 | TSHR (0.60) | LMNACASP6ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2947082-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | Pfizer Inc (US) | 2015-11-25 | — | — | EP | disclosed |
| US-9139587-B2 | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2015-09-22 | — | — | US | disclosed |
| EP-2676958-B1 | N1-Pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER (US) | 2015-07-01 | — | — | EP | disclosed |
| US-20140288111-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-8802690-B2 | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2014-08-12 | — | — | US | disclosed |
| EP-2676958-A1 | N1-Pyrazolospiroketone acetyl-CoA carboxylase inhibitors | Pfizer Inc. (US) | 2013-12-25 | — | — | EP | disclosed |
| EP-2499139-B1 | N1-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER (US) | 2013-12-11 | — | — | EP | disclosed |
| US-20130296319-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER INC. | 2013-11-07 | — | — | US | disclosed |
| US-8507681-B2 | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20130030181-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | PFIZER INC. (US) | 2013-01-31 | — | — | US | disclosed |
| WO-2011058473-A1 | N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20110111046-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | PFIZER INC | 2011-05-12 | — | — | US | disclosed |
| US-7879851-B2 | such as (E)-3-[2-(1-{[2-(5-Bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carbonyl]-amino}-cyclobutyl)-3-methyl-3H-benzoimidazol-5-yl]-acrylic Acid, used for the treatment of hepatitis C virus infections | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-01 | — | — | US | disclosed |
| US-7879851-B2 | such as (E)-3-[2-(1-{[2-(5-Bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carbonyl]-amino}-cyclobutyl)-3-methyl-3H-benzoimidazol-5-yl]-acrylic Acid, used for the treatment of hepatitis C virus infections | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-01 | — | — | US | disclosed |
| US-20110015203-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| US-20110015203-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| US-7582770-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-01 | — | — | US | disclosed |
| US-7582770-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-01 | — | — | US | disclosed |
| US-20090170859-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
| US-20090170859-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288111-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | ACACA, PC, ACACB | LMNA 2437/4885CASP6 4546/4885ALDH1A1 164/4885 |
| US-20110111046-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | ACACA, PC, ACACB | LMNA 2437/4885CASP6 4546/4885ALDH1A1 164/4885 |
| US-20130296319-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | ACACA, PC, ACACB | LMNA 2533/4885CASP6 4525/4885ALDH1A1 161/4885 |
| US-20090170859-A1 | Viral Polymerase Inhibitors | POLR2A, POLR1E, RPP30 | LMNA 3697/4885CASP6 4051/4885ALDH1A1 1822/4885 |
| US-20130030181-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | ACACA, PC, ACACB | LMNA 2437/4885CASP6 4546/4885ALDH1A1 164/4885 |
| US-20110015203-A1 | Viral Polymerase Inhibitors | POLR2A, POLR1E, RPP30 | LMNA 3697/4885CASP6 4051/4885ALDH1A1 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.